Literature DB >> 9655840

Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly.

Y Noda1, Y Miyamoto, T Mamiya, H Kamei, H Furukawa, T Nabeshima.   

Abstract

In the conditioned place preference test, phencyclidine (PCP) produces place aversion in naive rats, whereas PCP produces place preference in rats treated with PCP repeatedly. Although the PCP-induced place aversion is thought to involve the serotonergic system, the mechanisms of the PCP-induced place preference are unclear. We investigated whether the dopaminergic system is involved in place preference induced by PCP in mice repeatedly treated with PCP, because it is well known that the dopaminergic system plays an important role in the rewarding effect of drugs. PCP (2-8 mg/kg s.c.) induced a dose-dependent place aversion in naive mice, whereas PCP (2-8 mg/kg s.c.) induced a dose-dependent place preference in mice pretreated with PCP (10 mg/kg/day s.c.) for 28 days. The place preference induced by PCP (8 mg/kg s.c.) was attenuated significantly by alpha-methyl-rho-tyrosine (100 mg/kg i.p.), a tyrosine hydroxylase inhibitor, 6-hydroxydopamine (100 micrograms/mouse i.c.v.), a dopaminergic neurotoxin, and R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benza zepine (0.5 mg/kg s.c.), a dopamine D1 receptor antagonist. These agents themselves produced neither the place preference nor aversion. In contrast to the attenuating effects of these agents, N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (30 mg/kg i.p.), a noradrenergic neurotoxin, ritanserin (1 mg/kg i.p.), a serotonin2 receptor antagonist, and (-) sulpiride (50 and 100 mg/kg i.p.), a dopamine D2 receptor antagonist, failed to affect the PCP-induced place preference. In mice pretreated with methamphetamine (1 mg/kg/day s.c.) for 14 days, PCP (8 mg/kg s.c.) induced the place preference, but not aversion. These results demonstrate that the PCP-induced place preference depends on dopaminergic, but not on serotonergic and noradrenergic, neuronal systems and suggest a role for D1 receptors in the mediation of the PCP-induced place preference.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655840

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit.

Authors:  Y Miyamoto; K Yamada; Y Noda; H Mori; M Mishina; T Nabeshima
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

2.  Lower sensitivity to stress and altered monoaminergic neuronal function in mice lacking the NMDA receptor epsilon 4 subunit.

Authors:  Yoshiaki Miyamoto; Kiyofumi Yamada; Yukihiro Noda; Hisashi Mori; Masayoshi Mishina; Toshitaka Nabeshima
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

3.  The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release.

Authors:  Taku Nagai; Kiyofumi Yamada; Masako Yoshimura; Kazuhiro Ishikawa; Yoshiaki Miyamoto; Kazuki Hashimoto; Yukihiro Noda; Atsumi Nitta; Toshitaka Nabeshima
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-26       Impact factor: 11.205

4.  The Abuse Potential of Novel Synthetic Phencyclidine Derivative 1-(1-(4-Fluorophenyl)Cyclohexyl)Piperidine (4'-F-PCP) in Rodents.

Authors:  In Soo Ryu; Oc-Hee Kim; Young Eun Lee; Ji Sun Kim; Zhan-Hui Li; Tae Wan Kim; Ri-Na Lim; Young Ju Lee; Jae Hoon Cheong; Hee Jin Kim; Yong Sup Lee; Scott C Steffensen; Bong Hyo Lee; Joung-Wook Seo; Eun Young Jang
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

5.  Dysfunction of Serotonergic and Dopaminergic Neuronal Systems in the Antidepressant-Resistant Impairment of Social Behaviors Induced by Social Defeat Stress Exposure as Juveniles.

Authors:  Sho Hasegawa; Yuriko Miyake; Akira Yoshimi; Akihiro Mouri; Hirotake Hida; Kiyofumi Yamada; Norio Ozaki; Toshitaka Nabeshima; Yukihiro Noda
Journal:  Int J Neuropsychopharmacol       Date:  2018-09-01       Impact factor: 5.176

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.